Pipeline of CDH6-Targeted Immunotherapeutics

This competitive intelligence report about CDH6-Targeted Immunotherapeutics provides an up-to-date competitor evaluation in the field of therapy candidates in research and development targeting cadherin-6 (CDH6). This report will be prepared on demand within one working day upon order placement. The report lists active CDH6-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of anti-CDH6 immunotherapy candidates by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

Aberrant expression of the single-pass membrane glycoprotein Cadherin-6 (CDH6) has been reported in several human carcinomas, suggesting a possible role in metastasis and invasion. The expression of CDH6 is extremely low in normal tissues. Recently, antibody-drug conjugates (ADCs) targeting CDH6 have drawn attention to new cancer therapies and demonstrated their antitumor activity in preclinical models of epithelial ovarian cancer (EOC). CDH6 expression measured by immunohistochemistry is frequently observed in primary and recurrent EOC of all histotypes, especially in high-grade serous carcinoma. The frequency of CDH6 expression is consistent between primary and recurrent tumors. Thus, CDH6 is a promising therapeutic target for the treatment of EOC. In further studies, cadherin-6 was a top target candidate gene featuring frequent elevated mRNA expression in ovarian serous carcinoma and restricted expression across normal tissues. Extensive expression of CDH6 was also noticed in renal clear cell and papillary carcinoma, as well as in thyroid cancer.

Pipeline-leading raludotatug deruxtecan is an investigational specifically engineered potential first-in-class CDH6 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed with Merck & Co.. Raludotatug deruxtecan is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

In heavily pretreated platinum-sensitive ovarian cancer patients, raludotatug deruxtecan (R-DXd) showed promising preliminary efficacy at doses of 4.8–6.4 mg/kg among 45 patients and demonstrated a manageable safety profile. The ongoing REJOICE-Ovarian01 is a global, multicenter, randomized, open-label phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan in patients with platinum-resistant, high-grade ovarian, primary peritoneal or fallopian tube cancer.

Further ADCs and bispecific T-cell engagers are in the pipeline and will contribute to the evaluation of CDH6 as a viable clinical and commercial target.